These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 16818976

  • 21. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I, Balon BP, Rus I, Marc J.
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [Abstract] [Full Text] [Related]

  • 22. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
    Mesquita M, Wittersheim E, Demulder A, Dratwa M, Bergmann P.
    Adv Perit Dial; 2005 Mar; 21():181-4. PubMed ID: 16686314
    [Abstract] [Full Text] [Related]

  • 23. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N.
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [Abstract] [Full Text] [Related]

  • 24. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
    Grzegorzewska AE, Mlot M.
    Adv Perit Dial; 2005 May; 21():188-93. PubMed ID: 16686316
    [Abstract] [Full Text] [Related]

  • 25. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P.
    Circulation; 2005 May 17; 111(19):2461-8. PubMed ID: 15883214
    [Abstract] [Full Text] [Related]

  • 26. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.
    Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M.
    Arthritis Rheum; 2006 Jun 17; 54(6):1772-7. PubMed ID: 16736519
    [Abstract] [Full Text] [Related]

  • 27. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P, de la Higuera M, García DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, Escobar-Jiménez F, Muñoz-Torres M.
    Osteoporos Int; 2005 Nov 17; 16(11):1368-74. PubMed ID: 15711777
    [Abstract] [Full Text] [Related]

  • 28. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.
    Br J Haematol; 2004 Sep 17; 126(5):686-9. PubMed ID: 15327520
    [Abstract] [Full Text] [Related]

  • 29. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL.
    Calcif Tissue Int; 2005 Jan 17; 76(1):1-6. PubMed ID: 15455183
    [Abstract] [Full Text] [Related]

  • 30. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
    Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'Anna R, Corrado F, Bartolone S, Frisina N, Squadrito F.
    J Clin Endocrinol Metab; 2004 Jan 17; 89(1):188-92. PubMed ID: 14715848
    [Abstract] [Full Text] [Related]

  • 31. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.
    Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D.
    Clin Endocrinol (Oxf); 2004 Jan 17; 60(1):87-91. PubMed ID: 14678293
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 17; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 34. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.
    Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC, Pecherstorfer M.
    Anticancer Res; 2005 Aug 17; 25(5):3607-12. PubMed ID: 16101188
    [Abstract] [Full Text] [Related]

  • 35. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women.
    Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M.
    Clin Endocrinol (Oxf); 2004 Feb 17; 60(2):214-9. PubMed ID: 14725683
    [Abstract] [Full Text] [Related]

  • 36. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
    Ziegler S, Niessner A, Richter B, Wirth S, Billensteiner E, Woloszczuk W, Slany J, Geyer G.
    Metabolism; 2005 Jul 17; 54(7):935-8. PubMed ID: 15988704
    [Abstract] [Full Text] [Related]

  • 37. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.
    Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Choi MG, Yoo HJ, Park SW.
    Metabolism; 2005 Jan 17; 54(1):49-54. PubMed ID: 15562379
    [Abstract] [Full Text] [Related]

  • 38. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S, Montagnani A, Caffarelli C, Cadirni A, Campagna MS, Franci MB, Lucani B, Gaggiotti E, Nuti R.
    J Endocrinol Invest; 2005 Jun 17; 28(6):534-9. PubMed ID: 16117195
    [Abstract] [Full Text] [Related]

  • 39. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D.
    Am J Pathol; 2003 Nov 17; 163(5):2021-31. PubMed ID: 14578201
    [Abstract] [Full Text] [Related]

  • 40. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM.
    J Bone Miner Res; 2001 Jun 17; 16(6):1015-27. PubMed ID: 11393778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.